Anti-IL-23 and anti-IL-17 drugs for the treatment of non-pustular palmoplantar psoriasis: a real-life retrospective study

Figures & data

Table 1. Demographic and clinical characteristics at baseline of the two subgroups of patients.

	Anti-IL-17	Anti-IL-23
Number of patients, N (%)	59	60
Males, N (%)	34 (57.6)	33 (55)
Age, mean ± SD	58.59 ± 14.37	53.27 ± 15.80
BMI, mean ± SD	25.95 ± 4.14	26.68 ± 5.53
Disease Duration, mean ± SD	14.26 ± 14.65	13.61 ± 14.08
PsA, N (%)	11 (18.6)	12 (20)
≥ 1 Difficult-to-treat areas, N (%)	23 (39)	34 (56.7)
Cardiometabolic comorbidities, N (%)	19 (32.2)	22 (36.7)
Bio-Experienced, N (%)	16 (27.1)	18 (28.3)
PASI baseline, mean ± SD	8.67 ± 6.77	8.47 ± 5.67
ppPGA ≥ 4, N (%)	18 (30.5)	15 (25)

SD: Standard Deviation; BMI: Body Mass Index; PsA: Psoriatic Arthritis; PASI: Psoriasis Area and Severity Index; ppPGA: palmoplantar Psoriasis Global Assessment.

Figure 1. Proportion of patients achieving ppPGA 0/1 (clear or almost clear) at each time point in patients treated with anti-IL-23 and anti-IL-17. IL: Interleukin; ppPGA: palmoplantar Psoriasis Global Assessment

Data availability statement

Data available on request from the authors.